Nutriband Issues Letter to ShareholdersORLANDO, Fla., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (
NASDAQNTRB)
NASDAQ: NTRBWNASDAQNTRBW)
Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal TechnologyNutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets.
Nutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4thORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (Nasdaq:NTRB)(Nasdaq:NTRBW) today announced that it will be presenting at the Noble Conference taking place December 3rd and 4th at the Florida Atlantic University in Boca Raton, FL. Company President and Chairman Serguei Melnik will present at 1.30 PM in Conference room 3 on December 4th to primarily discuss the company’s AVERSA technology.
Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa RicaThe approved product will be exclusively distributed through Farmavision S.A. throughout Costa Rica
Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of DirectorsThe Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placement
Nutriband Inc. Announces $8.4M Private PlacementNutriband is targeting a 505(b)(2) NDA to the FDA for marketing approval of AVERSA™ Fentanyl in Q1 2025
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate AbusePALM BEACH, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Abuse-deterrent transdermal technology can be used to prevent the misuse of drugs with abuse potential, such as fentanyl, by incorporating aversive agents into transdermal patches. Abuse-deterrent opioid formulations (ADFs) are designed to make it more difficult to abuse opioids by making them less attractive or rewarding, or by increasing the difficulty of manipulating them. ADFs can help reduce the risk of adverse effects associated with snorting or injecting opioids, and may also help prevent medication errors. Active companies in the industry include: Nutriband Inc. (
NASDAQNTRB), Teva Pharmaceutical Industries Ltd.
NYSE: TEVANYSETEVA)
(NYSE: LLYNYSELLY
, Novartis AG (NYSE: NVSNYSE
), Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX
AMRX).
NUTRIBAND RECEIVES CHINA PATENT NOTICE OF ALLOWANCE FOR ITS AVERSA™ ABUSE DETERRENT TRANSDERMAL TECHNOLOGYNotice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for a patent application covering its Nutriband AVERSA™ abuse deterrent transdermal technology Nutriband abuse-deterrent transdermal technology consists of a proprietary aversive agent coating that employs taste aversion to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products […]
Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal TechnologyNotice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology
Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal PatchNutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in the world, as an aversive agent for its Aversa™ Fentanyl abuse deterrent fentanyl transdermal patch
Nutriband Inc. Authorizes $1M Share Buyback ProgramORLANDO, FL / ACCESSWIRE / September 16, 2024 / Nutriband Inc. (
NASDAQNTRB)
NASDAQ:NTRBWNASDAQNTRBW)
Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA SubmissionPrivate Placement of $8.4 million has closed and will fund the commercial development of lead product AVERSA Fentanyl to NDA filing
Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal PatchNDA will be primarily based on a single Phase 1 human abuse potential clinical study with no Phase 2 or 3 clinical trials needed prior to submission.
